title: Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.
abstract: OBJECTIVE
  The hepatitis C virus (HCV) which infects 3% of the world's population is a global challenge. Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFNα/RBV) combination therapy in patients infected with HCV genotype 1. IL28B gene rs8099917 polymorphism should be determined before beginning treatment of HCV-infected patients to predict an individual's response. The aims of this study were to analyze the correlation between IL28B gene rs8099917 (T/G) polymorphism and PegIFNα/RBV therapy outcome in the Turkish population.
  
  
  METHODS
  Genotypes of the IL28B gene rs8099917 (T/G) single nucleotide polymorphism (SNP) were determined in 308 patients with HCV infection by using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. One group consisted of 148 patients with a sustained virological response (SVR), whereas the second group consisted of 160 nonresponders (non-SVR).
  
  
  RESULTS
  Allele and genotype associations of IL28B gene rs8099917 polymorphism with a sustained virological response were observed in comparisons between the SVR and non-SVR groups (P<0.001). In addition, the characteristics of the subjects did not differ between these two groups except for age and fibrosis stage (P<0.05). Additionally, neither SVR nor rs80999917 genotypes were associated by HCV RNA levels.
  
  
  CONCLUSIONS
  In conclusion, the rs8099917 polymorphism was thus found strongly associated with a sustained virological response to therapy in Turkish patients infected with HCV genotype 1. Consequently, we suggest determining IL28B gene rs8099917 polymorphism of patients with HCV genotype 1 before onset of treatment.
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: hakkiz@superonline.com.
authors: Hikmet
authors: H
authors: Akkız
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: ersin0571@gmail.com.
authors: Ersin
authors: E
authors: Akgöllü
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: abekar@gmail.com.
authors: Aynur
authors: A
authors: Bekar
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: selcukyldrm1988@gmail.com.
authors: Selçuk
authors: S
authors: Yıldırım
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: macitsandikci@yahoo.com.
authors: Macit
authors: M
authors: Sandıkçı
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: yakup73us@yahoo.com.
authors: Yakup
authors: Y
authors: Ülger
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: berrinyalinbas@hotmail.com.
authors: Berrin
authors: B
authors: Yalınbaş Kaya
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: sedef.kuran@gmail.com.
authors: Sedef
authors: S
authors: Kuran
authors: Çukurova University, Faculty of Medicine, Department of Gastroenterology, 01330 Adana, Turkey. Electronic address: ouskudar@hotmail.com.
authors: Oğuz
authors: O
authors: Üsküdar
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D014421:Turkey; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda